Press Release
​
KeV Medical Imaging and Telix Pharmaceuticals Announces European Launch of QDOSE Following MDR Certification
Athens, Greece — October 1st 2025
​
KeV Medical Imaging and Telix Pharmaceuticals today announced the European availability of QDOSE®, advanced medical dosimetry software. Following European Union (EU) Medical Device Regulation (MDR) certification achieved earlier this year, QDOSE® is now ready for adoption by hospitals across Europe, supporting the safe and effective integration of therapeutic and diagnostic radiopharmaceuticals (“theranostics”) into clinical practice.
​
Personalized radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimizing treatment response while reducing effects on normal healthy organs and optimizing the use of isotope supply chains.
​
Telix holds the intellectual property rights and leads development of QDOSE®, while KeV Medical Imaging serves as Telix’s strategic partner in Europe, as manufacturer and customer support provider. Together, the companies aim to make advanced dosimetry more accessible, reliable, and impactful for European healthcare providers.
​
“At KeV Medical Imaging, we are proud to serve as Telix’s strategic partner in Europe for QDOSE. By combining our nuclear medicine expertise with 24/7 application support, we aim to ensure that hospitals and clinicians can confidently integrate QDOSE into their practice for the benefit of patients,” said Kostopoulos Konstantinos, General Manager at KeV Medical Imaging.
​
“Telix is committed to advancing the field of theranostics with innovative solutions like QDOSE. Partnering with KeV Medical Imaging ensures that our European customers receive not only a certified and reliable product, but also the expert support needed to maximize the value of QDOSE in clinical practice,” said Nynke van den Berg, General Manager Medical Technologies at Telix Pharmaceuticals.
​
KeV (booth #128) will be at EANM and is organizing a QDOSE® workshop on Sunday October 5, 2025 from 12:30-14:00.
You can register on https://www.qdose.net/event-details/qdose-r-workshop-eanm-2025
​
About QDOSE®
QDOSE® is an advanced, molecular imaging dosimetry software. It is a versatile, stand-alone, and lightweight tool with functionalities and workflows needed to perform comprehensive internal radiation dose assessments — together with unprecedented workflow support and consistency checking. The product features organ segmentation, single time-point dosimetry, and planar, hybrid and volumetric dosimetry capabilities, supported by algorithms for fast data processing and an extensive radionuclide database. Integrated with IDAC-DOSE2.1, QDOSE® provides reliable estimates of radiation absorbed dose to organs and tissues from medically administered radiopharmaceuticals, including total-body effective dose. Absorbed dose calculations are based on clinical measurements of radioactivity biodistributions and biokinetics. QDOSE® is intended for applications in clinical nuclear medicine, molecular radiotherapy, radiation safety evaluations, risk assessment, record-keeping, and regulatory compliance. QDOSE® is intended for use by professionals (medical physicists, radiologists and oncologists including nuclear medicine physicians), radiologic imaging technologists, health physicists and radiation safety officers and administrators, students in training, and others having interest in ability to calculate internal radiation doses from medically administered radiopharmaceuticals.
​
QDOSE® dosimetry software has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is Conformité Européenne (CE) marked and Medical Device Regulation (MDR) certified for clinical use within the European Union (EU).
Visit www.qdose.net for further information.
​
About KeV Medical Imaging
KeV Medical Imaging is a specialized medical technology company focused exclusively on nuclear medicine. Based in Europe, KeV provides manufacturing, regulatory compliance, and 24/7 application support for advanced software solutions in theranostics and dosimetry. By combining technical expertise with dedicated customer support, KeV helps hospitals and clinicians integrate innovative tools to improve patient care.
​
About Telix Pharmaceuticals
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe , and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information.
Media Contact:
Frima Nausika
PRRC
frima@kevimaging.gr
+30 6940771326